Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Lamisil, Lamisil At. Every FDA application for this active ingredient: 6 branded and 17 generic.
As of Nov 22, 2026, FDA lists 23 applications for Terbinafine hydrochloride (sold as Lamisil, Lamisil At), first approved Dec 30, 1992, with 2 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Terbinafine HCl
Part D
$11.5M
+19%
465,320
Medicaid spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Terbinafine
$6.0M for 442,556 prescriptions, +7% on 2024
What pharmacies pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Terbinafine HCl 250 mg tablet: $0.143 per unitGeneric · −5% in a year
How its trials ended
25 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Completed, result not reported1768%Completed, result not reportedCount17Share68%
Ongoing312%OngoingCount3Share12%
Status unknown312%Status unknownCount3Share12%
Met its primary endpoint14%Met its primary endpointCount1Share4%
Stopped: sponsor or business decision14%Stopped: sponsor or business decisionCount1Share4%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA